Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Aug 25, 2014 12:31 PM Flag

    UBS reiterates buyout candidates today

    UBS analyst Andrew Peters and team look for other biotech companies that could be in play:

    "While we had viewed InterMune as a top take-out candidate in biotech, we also note our Buy rating on Achillion Pharmaceuticals (ACHN) shares also reflects M&A potential. Further, the premium paid on shares and the likely competitive process underscores the relative scarcity of de-risked high quality assets, and we also highlight Puma Biotechnology (PBYI), Incyte (INCY), Insmed (INSM), and Medivation (MDVN) as potential targets among smid-cap names in our coverage universe."

    Sentiment: Buy

 
INSM
14.76-0.24(-1.60%)Sep 23 4:00 PMEDT